In-depth Immunological Investigation of COVID-19.

Conditions

Coronavirus Infections

Keywords

COVID-19

Brief summary

The COntAGIouS trial (COvid-19 Advanced Genetic and Immunologic Sampling; an in-depth characterization of the dynamic host immune response to coronavirus SARS-CoV-2) proposes a transdisciplinary approach to identify host factors resulting in hyper-susceptibility to SARS-CoV-2 infection, which is urgently needed for directed medical interventions.

Detailed description

The overall aim of this prospective study is to provide an in-depth characterization of clinical and immunological features of patients hospitalized in UZ Leuven because of SARS-CoV-2 infection. For this purpose, clinical data and blood, nasopharyngeal/rectal swab, and if safe, bronchoalveolar lavage (BAL) fluid and lung tissue samples will be collected from PCR- or CT-confirmed COVID-19 patients, with varying degrees of disease severity. Assessed characteristics will be compared between severe and non-severe COVID-19 patients, and between COVID-19 positive and negative ('control') patients.

Feys S, Vanmassenhove S, Kraisin S, Yu K, Jacobs C, Boeckx B, Cambier S, Cunha C, Debaveye Y, Gonçalves SM, Hermans G, Humblet-Baron S, Jansen S, Lagrou K, Meersseman P, Neyts J, Peetermans M, Rocha-Pereira J, Schepers R, Spalart V, Starick MR, Thevissen K, Van Brussel T, Van Buyten T, Van Mol P, Vandenbriele C, Vanderbeke L, Wauters E, Wilmer A, Van Weyenbergh J, Van De Veerdonk FL, Carvalho A, Proost P, Martinod K, Lambrechts D, Wauters J.

2024-01-2418 citations

10.1016/s2666-5247(23)00368-3

Establishing a Unified COVID-19 “Immunome”: Integrating Coronavirus Pathogenesis and Host Immunopathology

Els Wauters, Karin Thevissen, Carine Wouters, Francesca M. Bosisio, Frederik De Smet et al. (16 authors)

Frontiers in Immunology2020-07-0314 citations

10.3389/fimmu.2020.01642

Interventions

OTHERPatient sampling

Blood draw, NP/rectal swab, bronchoscopy if clinically indicated, lung tissue if applicable

Study design

Observational model

OTHER

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

No

Inclusion criteria

* Patients \>/= 18 years old AND * Hospitalised with PCR-confirmed and/or CT-confirmed SARS-CoV-2 disease

Exclusion criteria

* Age \< 18 years old * No informed consent

Design outcomes

Primary

Measure	Time frame	Description
Clinical Features	6 months	Description of clinical, laboratory and radiological features of illness and complications.
Immune host response at systemic level	6 months	Evaluation of dynamic host immune response at systemic level (immune signalling molecules in plasma, peripheral blood mononuclear cell isolation for advanced immunophenotyping and transcriptomics). Real-time analysis using CyTOF will be performed as screening, in combination with in-depth immunophenotyping.
Immune host response at local level	6 months	Evaluation of dynamic host immune response at systemic level (immune signalling molecules in plasma, peripheral blood mononuclear cell isolation for advanced immunophenotyping and transcriptomics).
Host genetic variation	6 months	Identification of host genetic variants that are associated with severity of disease.

Secondary

Measure	Time frame	Description
Comparison severe and non-severe COVID-19 hospitalised patients	6 months	Differences in baseline factors
Correlation of findings with outcome	6 months	Correlation of findings with outcome, aiming to identify early biomarkers of severe disease and putative targets for immunomodulatory therapy
Correlation of immune profiling - microbiome	6 months	Correlation of immune profiling with microbiome analysis of patients

Countries

Belgium

Contacts

CONTACTJoost Wauters, MD PhD

joost.wauters@uzleuven.com003216344275

PRINCIPAL_INVESTIGATORJoost Wauters, MD PhD

UZ Leuven

Outcome results

None listed